ORIGINAL_ARTICLE
Effect of an educational intervention based on BASNEF model on treatment adherence after coronary artery bypass surgery: A randomized clinical trial
BACKGROUND: Coronary artery bypass graft (CABG) surgery is the most effective treatment for cardiovascular disease (CVD). Adherence to treatment after CABG surgery is very important. One of the educational models used in this regard is the BASNEF (Belief, Attitudes, Subjective Norms, and Enabling Factors) model. The present study aimed to assess the effect of an educational intervention based on BASNEF model on adherence to treatment in patients after CABG surgery.METHODS: The present study was a randomized clinical trial. In this study, 72 patients who had undergone CABG surgery participated in the two intervention and control groups. Patients in the intervention group took part in 4 40-minute educational sessions based on BASNEF model after discharge. The patients in both groups completed the Modanloo Adherence to Treatment Questionnaire (MATQ) and a researcher-made BASNEF model questionnaire before the intervention, after the educational intervention, and at the 3-month follow-up. Data were analyzed using independent t-test, chi-square test, Man-Whitney test, and repeated measures analysis of variance (ANOVA). Mauchly’s sphericity test was used for testing sphericity and the Greenhouse-Geisser correction was used in the case of lack of sphericity. All P-values of less than 0.05 were considered significant.RESULTS: The total score of the MATQ and its subscales had significantly improved in the intervention group after the intervention compared with the control group (P < 0.050). In addition, the mean scores of the model constructs (knowledge, attitude, behavior intention, subjective norms, and enabling factors) had significantly improved after the intervention in the intervention group in comparison with the control group (P < 0.050).CONCLUSION: The educational intervention based on BASNEF model improved adherence to treatment in patients after CABG surgery. Moreover, the model constructs improved in the intervention group in comparison with the control group after the intervention.
https://arya.mui.ac.ir/article_10729_f07609f5cf364d0cd7ade722f78ffa10.pdf
2020-07-05
105
114
10.22122/arya.v16i3.2062
Treatment Adherence
Coronary Artery Bypass Graft Surgery
Educational Models
Atefeh
Torknejad
torknejad@mailinator.com
1
MSc Student, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Sima
Babaei
babaee@nm.mui.ac.ir
2
Assistant Professor, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Mohsen
Mirmohammadsadeghi
mirmohammadsadeghi@mailinator.com
3
Associate Professor, Chamran Medical and Research Heart Center AND Department of Cardiac Surgery, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Suaya JA, Stason WB, Ades PA, Normand SL, Shepard DS. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009; 54(1): 25-33.
1
Hosseinian A, Kasayi V, Mohammadzade A, Habibzadeh S, Saghi F, Davari M, et al. Evaluation of early complications of coronary artery bypass grafting surgery (CABGS) in the first month after operation in imam Khomeini hospital of Ardabil during 2013-2014. J Ardabil Univ Med Sci 2014; 14(1): 18-27. [In Persian].
2
Liu H, Xu Z, Gu H, Li W, Chen W, Sun C, et al. Common variant in glycoprotein ia increases long-term adverse events risk after coronary artery bypass graft surgery. J Am Heart Assoc 2016; 5(12).
3
Shafiee Z, Babaee S, Nazari A, Atashi V. The effect of massage therapy on sleep quality of patients after coronary artery bypass graft operation. Iranian Journal of Cardiovascular Nursing 2013; 2(2): 22-9. [In Persian].
4
Rouhi Balasi L, Paryad E, Kazemnezhad L, Bouraki S, Sadeghi Meybodi AM, Nasiri Sheikhani N. Study status of care adherence and its related factors in patients undergoing coronary artery bypass surgery. Holist Nurs Midwifery 2015; 25(3): 34-45. [In Persian].
5
Iakovleva MV. Adherence to treatment after coronary bypass surgery: Psychological aspects. Revista Iberoamericana de Psicologia y Salud 2016; 7(1): 9-14.
6
Salari A, Hasandokht T, Mahdavi-Roshan M, Kheirkhah J, Gholipour M, Pouradollah TM. Risk factor control, adherence to medication and follow up visit, five years after coronary artery bypass graft surgery. J Cardiovasc Thorac Res 2016; 8(4): 152-7.
7
Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: A meta-analysis. Med Care 2009; 47(8): 826-34.
8
Levesque A, Li HZ, Pahal JS. Factors related to patients' adherence to medication and lifestyle change recommendations: Data from Canada. Int J Psychol Stud 2012; 4(2): 42.
9
Sanaie N, Nejati S, Zolfaghari M, Alhani F, Kazemnezhad A. The effects of family-based empowerment on family cooperation in following patient treatment regime after coroner arteries bypass surgery. Modern Care 2014; 11(1): 19-27. [In Persian].
10
Safaie Sarnaghi M, Hemmati Maslak Pak M, Khademvatan K, Alinejhad V. The effect of short message service on adherence to treatment advice in the patients with hypertension. J Urmia Nurs Midwifery Fac 2016; 14(3): 224-32. [In Persian].
11
Mohamaei F, Nouri Tajer M, Nouhi F, Maleki M. Application of basnef health belief model in preventing the occurrence of risk factors contributing to myocardial infarction in patients with coronary artery disease. Iranian Heart Journal 2004; 5(1-2): 29-32. [In Persian].
12
Veronovici NR, Lasiuk GC, Rempel GR, Norris CM. Discharge education to promote self-management following cardiovascular surgery: An integrative review. Eur J Cardiovasc Nurs 2014; 13(1): 22-31.
13
Taghadosi MH, Madadzadeh N, Shadzi SH, Hasanzadeh A. Effects of education interventions on the coke workers' immune performances on BAZNEF model basis at Isfahan melting factory, 2005. J Ilam Univ Med Sci 2008; 16(3): 20-9. [In Persian].
14
Izadirad H, Masoudi GR, Zareban I, Shahraki Poor M, Jadgal K. The effect of educational program based on BASNEF model on women's blood pressure with hypertension. Journal of Torbat Heydariyeh University of Medical Sciences 2013; 1(2): 22-31. [In Persian].
15
Baghianimoghadam MH, Rahaee Z, Morowatisharifabad MA, Sharifirad G, Andishmand A, Azadbakht L. Effects of education on self-monitoring of blood pressure based on BASNEF model in hypertensive patients. J Res Med Sci 2010; 15(2): 70-7.
16
Khani Jeihooni A, Kashfi SM, Hazavehei SM. Effects of the BASNEF Model-Based Educational Programs on Blood Sugar Control, (Type 2 Diabetes). J Educ Health Promot 2013; 1(1): 33-49. [In Persian].
17
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009; 119(23): 3028-35.
18
Nilsson UG, Ivarsson B, Alm-Roijer C, Svedberg P. The desire for involvement in healthcare, anxiety and coping in patients and their partners after a myocardial infarction. Eur J Cardiovasc Nurs 2013; 12(5): 461-7.
19
Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: A comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007; 44(8): 1468-77.
20
Seyed Fatemi N, Rafii F, Hajizadeh E, Modanloo M. Psychometric properties of the adherence questionnaire in patients with chronic disease: A mix method study. Koomesh 2018; 20(2): 179-91. [In Persian].
21
Meng K, Seekatz B, Haug G, Mosler G, Schwaab B, Worringen U, et al. Evaluation of a standardized patient education program for inpatient cardiac rehabilitation: Impact on illness knowledge and self-management behaviors up to 1 year. Health Educ Res 2014; 29(2): 235-46.
22
Tol A, Farhandi H, Mohebbi B, Sadeghi R. BASNEF Model intervention on blood pressure modification among hypertensive diabetic patients. J Educ Health Promot 2017; 6: 47.
23
Ghisi GL, Grace SL, Thomas S, Vieira AM, Costa IZ, Oh P. Knowledge and exercise behavior maintenance in cardiac rehabilitation patients receiving educational interventions. Heart Lung 2015; 44(6): 474-80.
24
Sarayloo K, Moghadam ZB, Mansoure JM, Mostafa H, Mohsen S. The impact of an educational program based on BASNEF model on the selection of a contraceptive method in women. Iran J Nurs Midwifery Res 2015; 20(2): 171-8.
25
Poshtchaman Z, Jadid Milani M, Atashzadeh Shoorideh F, Akbarzadeh Bagheban A. Assessing patient adherence to treatment after coronary artery bypass graft. J Sabzevar Univ Med Sci 2015; 22(4): 668-75. [In Persian].
26
Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence using a multidimensional adherence model in patients with heart failure. J Card Fail 2008; 14(7): 603-14.
27
Aggarwal B, Liao M, Allegrante JP, Mosca L. Low social support level is associated with non-adherence to diet at 1 year in the Family Intervention Trial for Heart Health (FIT Heart). J Nutr Educ Behav 2010; 42(6): 380-8.
28
Gance-Cleveland B. Motivational interviewing as a strategy to increase families' adherence to treatment regimens. J Spec Pediatr Nurs 2005; 10(3): 151-5.
29
Lin HH, Tsai YF, Lin PJ, Tsay PK. Effects of a therapeutic lifestyle-change programme on cardiac risk factors after coronary artery bypass graft. J Clin Nurs 2010; 19(1-2): 60-8.
30
French DP, Cooper A, Weinman J. Illness perceptions predict attendance at cardiac rehabilitation following acute myocardial infarction: A systematic review with meta-analysis. J Psychosom Res 2006; 61(6): 757-67.
31
World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: WHO; 2003.
32
Chien WT, Chiu YL, Lam LW, Ip WY. Effects of a needs-based education programme for family carers with a relative in an intensive care unit: A quasi-experimental study. Int J Nurs Stud 2006; 43(1): 39-50.
33
ORIGINAL_ARTICLE
The factors related to hospitalization period in patients with acute myocardial infarction treated after primary percutaneous coronary intervention
BACKGROUND: Decreasing the hospital length of stay (LOS) in ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PPCI) is an issue which is related to reducing hospital costs. This study was aimed to determine the average number of hospital LOS among patients with STEMI treated by PPCI and predictors of longer LOS.METHODS: This cross-sectional study was performed on 561 patients with STEMI who referred to Heshmat Hospital, Rasht, north of Iran, within 2015-2018. As soon as STEMI was detected, patients were transferred to the catheterization laboratory (cath lab) in the shortest possible time and underwent PPCI. A questionnaire including characteristics of patients, procedures, and in-hospital adverse events was completed. Data were analyzed with SPSS software.RESULTS: The mean age of patients was 59.36 ± 11.90 years. 74.2% (n = 416) of subjects were men and 25.8% (n = 145) were women. The hospital LOS of 3 to 6 days had the highest prevalence up to 47%. The results of the multiple logistic regression showed that risk of hospital LOS > 6 days in unsuccessful percutaneous coronary intervention (PCI) was 33.2 versus 66.8 in successful PCI (P = 0.001). Moreover, the risk of hospital LOS > 6 days in subjects who had post-procedure complication, problems at admission, and primary comorbidities was 9.13 (7.22-11.53)-fold, 4.09 (2.86-5.85)-fold, and 1.75 (1.35-2.27)-fold more than those who had not, respectivelyCONCLUSION: By identifying controllable predictive factors associated with prolonged hospitalization after PPCI, the length of hospitalization can be decreased; also, the patient remission can be enhanced and hospital costs reduced.
https://arya.mui.ac.ir/article_10730_38d14be74232ee9a3a411658e9be735d.pdf
2020-07-05
115
122
10.22122/arya.v16i3.1915
Myocardial Infarction
Percutaneous Coronary Intervention
Length of Stay
Fardin
Mirbolouk
mirbolouk@mailinator.com
1
Associate Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Arsalan
Salari
salari@mailinator.com
2
Associate Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Mahboobeh
Gholipour
gholipour@mailinator.com
3
Assistant Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Salman
Nikfarjam
nikfarjam@mailinator.com
4
Assistant Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Reza
Pourbahador
pourbahador@mailinator.com
5
Assistant Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Hamideh
Mohamadnia
mohamadnia@mailinator.com
6
Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Niloufar
Akbari-Parsa
niloufarakbariparsa@gmail.com
7
Assistant Professor, Cardiovascular Diseases Research Center AND Heshmat Hospital, Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
LEAD_AUTHOR
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 2010; 35(2): 72-115.
1
Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 2013; 168(2): 934-45.
2
Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, et al. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med 2014; 17(5): 304-20.
3
Schlatter RP, Hirakata VN, Polanczyk CA. Estimating the direct costs of ischemic heart disease: evidence from a teaching hospital in BRAZIL, a retrospective cohort study. BMC Cardiovasc Disord 2017; 17(1): 180.
4
Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: The Isfahan Cohort Study. Arch Iran Med 2013; 16(3): 138-44.
5
Smith EJ, Mathur A, Rothman MT. Recent advances in primary percutaneous intervention for acute myocardial infarction. Heart 2005; 91(12): 1533-6.
6
Koyanagi R, Hagiwara N, Kasanuki H, Tsurumi Y, Ogawa H. Primary percutaneous coronary intervention vs conservative treatment for acute ST elevation myocardial infarction: Short-and long-term follow-up according to disease severity. Circ J 2008; 72(9): 1391-6.
7
Charytan DM, Desai M, Mathur M, Stern NM, Brooks MM, Krzych LJ, et al. Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int 2016; 90(2): 411-21.
8
Iwasaki K. Myocardial ischemia is a key factor in the management of stable coronary artery disease. World J Cardiol 2014; 6(4): 130-9.
9
Noman A, Zaman AG, Schechter C, Balasubramaniam K, Das R. Early discharge after primary percutaneous coronary intervention for
10
ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2013; 2(3): 262-9.
11
Schellings DA, Ottervanger JP, van 't Hof AW, de Boer MJ, Dambrink JH, Hoorntje JC, et al. Predictors and importance of prolonged hospital stay after primary PCI for ST elevation myocardial infarction. Coron Artery Dis 2011; 22(7): 458-62.
12
Resnic FS, Shah SP. Balloon-to-door time: Emerging evidence for shortening hospital stay after primary PCI for STEMI. J Am Coll Cardiol 2015; 65(12): 1172-4.
13
Antoni ML, Boden H, Delgado V, Boersma E, Fox K, Schalij MJ, et al. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012; 33(1): 96-102.
14
Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol 1998; 31(5): 967-72.
15
Kotowycz MA, Syal RP, Afzal R, Natarajan MK. Can we improve length of hospitalization in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention? Can J Cardiol 2009; 25(10): 585-8.
16
Isik T, Ayhan E, Uluganyan M, Gunaydin ZY, Uyarel H. Predictors of prolonged in-hospital stay after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Angiology 2016; 67(8): 756-61.
17
Zeymer U, Arntz HR, Dirks B, Ellinger K, Genzwurker H, Nibbe L, et al. Reperfusion rate and inhospital mortality of patients with ST segment elevation myocardial infarction diagnosed already in the prehospital phase: results of the German Prehospital Myocardial Infarction Registry (PREMIR). Resuscitation 2009; 80(4): 402-6.
18
Ahmadi A, Sajjadi H, Etemad K, Khaledifar A, Mobasherii M. Epidemiological Characteristics and Determinants of Mortality in Acute Coronary Syndrome in Iran. J Mazandaran Univ Med Sci 2015; 25(124): 1-9. [In Persian].
19
Karabulut A, Cakmak M, Uzunlar B, Bilici A. What is the optimal length of stay in hospital for ST elevation myocardial infarction treated with primary percutaneous coronary intervention? Cardiol J 2011; 18(4): 378-84.
20
Swaminathan RV, Rao SV, McCoy LA, Kim LK, Minutello RM, Wong SC, et al. Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: A report from the National
21
Cardiovascular Data Registry. J Am Coll Cardiol 2015; 65(12): 1161-71.
22
Melberg T, Jorgensen M, Orn S, Solli T, Edland U, Dickstein K. Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: A randomized trial. Eur J Prev Cardiol 2015; 22(11): 1427-34.
23
ORIGINAL_ARTICLE
The comparison of procedural and clinical outcomes of thrombolytic-facilitated and primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction (STEMI): Findings from PROVE/ACS study
BACKGROUND: There is still a controversy in the preferred method of reperfusion in acute ST-segment elevation myocardial infarction (STEMI), when the achievement of well-defined "golden time" is difficult. We sought to evaluate the procedural and in-hospital outcomes of the strategy of "thrombolytic administration and rescue or routine percutaneous coronary intervention (PCI)" versus "primary PCI (PPCI)" strategy in acute STEMI.METHODS: In this observational prospective study, the data of 237 patients with acute STEMI presented or referred to Chamran Cardiovascular Research Center in Isfahan, Iran, were collected (PROVE/ACS study). Baseline characteristics, thrombolysis in myocardial infarction (TIMI) flow grade of infarct-related artery (IRA), left ventricular ejection fraction (LVEF), and in-hospital outcomes were evaluated.RESULTS: The mean age of patients was 61.4 ± 13.0 years, 86.9% were men, 13.1% were diabetic, and 67.9% had anterior STEMI. Patients in the "thrombolytic then PCI" group were younger, more smoker, more often male with higher body weight and lower systolic blood pressure (SBP). The pre-PCI TIMI flow grade 3 was more often seen in the "thrombolytic then PCI" group (39.4% vs. 21.0%, P < 0.001) and less thrombectomy was performed in this group of patients (12.9% vs. 26.7%, P = 0.011). Time to reperfusion was significantly longer in PPCI group (182.4 ± 233.7 minutes vs. 44.6 ± 93.4 minutes, respectively, P < 0.001). No difference in mortality, mean of LVEF, and incidence of atrial fibrillation (AF) was observed in two groups.CONCLUSION: If the PPCI strategy could not be performed in the golden time, the strategy of thrombolytic administration and rescue or routine PCI leads to more initial IRA patency and less thrombectomy with similar clinical outcomes.
https://arya.mui.ac.ir/article_10731_48403f29a0591a4d64018e7d232fad7e.pdf
2020-07-05
123
129
10.22122/arya.v16i3.1869
ST Segment Elevation Myocardial Infarction
Percutaneous Coronary Intervention
Thrombolytic Therapy
Treatment Outcome
Reperfusion
Maryam
Soleimani
soleimani@mailinator.com
1
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Azam
Soleimani
asoleimanii@gmail.com
2
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Hamidreza
Roohafza
hroohafza@gmail.com
3
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nizal
Sarrafzadegan
sarrafzadegan@mailinator.com
4
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Marzieh
Taheri
taheri@mailinator.com
5
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Ghasem
Yadegarfar
yadegarfar@mailinator.com
6
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Maedeh
Azarm
azarm@mailinator.com
7
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Neda
Dorostkar
dorostkar@mailinator.com
8
Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hajar
Vakili
vakili@mailinator.com
9
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoumeh
Sadeghi
sadeghi@mailinator.com
10
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119-77.
1
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61(4): e78-e140.
2
Al Shammeri O, Garcia L. Thrombolysis in the age of primary percutaneous coronary intervention: Mini-review and meta-analysis of early PCI. Int J Health Sci (Qassim) 2013; 7(1): 91-100.
3
Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010; 55(2): 102-10.
4
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368(15): 1379-87.
5
Danchin N, Puymirat E, Steg PG, Goldstein P, Schiele F, Belle L, et al. Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: The French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort. Circulation 2014; 129(16): 1629-36.
6
Victor SM, Subban V, Alexander T, Bahuleyan CG, Srinivas A, Selvamani S, et al. A prospective, observational, multicentre study comparing tenecteplase facilitated PCI versus primary PCI in Indian patients with STEMI (STEPP-AMI). Open Heart 2014; 1(1): e000133.
7
Thiele H, Eitel I, Meinberg C, Desch S, Leuschner A, Pfeiffer D, et al. Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: The LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction). JACC Cardiovasc Interv 2011; 4(6): 605-14.
8
Denktas AE, Athar H, Henry TD, Larson DM, Simons M, Chan RS, et al. Reduced-dose fibrinolytic acceleration of ST-segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry. JACC Cardiovasc Interv 2008; 1(5): 504-10.
9
Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: A 5-year follow-up. Eur Heart J 2009; 30(13): 1598-606.
10
Givi M, Sarrafzadegan N, Garakyaraghi M, Yadegarfar G, Sadeghi M, Khosravi A, et al. Persian Registry of cardioVascular diseasE (PROVE): Design and methodology. ARYA Atheroscler 2017; 13(5): 236-44.
11
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012; 126(16): 2020-35.
12
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2017; 40(Suppl 1): S11-S24.
13
Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future? JAMA 2005; 293(8): 979-86.
14
Sim DS, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction: A propensity score-matched analysis. Circ Cardiovasc Interv 2016; 9(9).
15
Victor SM, Vijayakumar S, Alexander T, Bahuleyan CG, Srinivas A, Selvamani S, et al. Two-year follow-up data from the STEPP-AMI study: A prospective, observational, multicenter study comparing tenecteplase-facilitated PCI versus primary PCI in Indian patients with STEMI. Indian Heart J 2016; 68(2): 169-73.
16
Roule V, Ardouin P, Blanchart K, Lemaitre A, Wain-Hobson J, Legallois D, et al. Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. Crit Care 2016; 20(1): 359.
17
Brodie BR. Facilitated percutaneous coronary intervention still searching for the right patients. JACC Cardiovasc Interv 2011; 4(6): 615-7.
18
Rashid MK, Guron N, Bernick J, Wells GA, Blondeau M, Chong AY, et al. Safety and efficacy of a pharmacoinvasive strategy in ST-segment elevation myocardial infarction: A patient population study comparing a pharmacoinvasive strategy with a primary percutaneous coronary intervention strategy within a regional system. JACC Cardiovasc Interv 2016; 9(19): 2014-20.
19
Van de Werf F. Reperfusion treatment in acute myocardial infarction in elderly patients. Kardiol Pol 2018; 76(5): 830-7.
20
ORIGINAL_ARTICLE
Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease
BACKGROUND: Evermine 50™ (Meril Life Sciences Pvt. Ltd., India) everolimus-eluting stent system (EES) is a novel ultrathin strut (50 µm) cobalt-chromium coronary drug-eluting stent (DES) platform with biodegradable polymer coating. The Evermine 50 EES-KLES study aimed to evaluate the Evermine 50 EES in terms of 24-month clinical safety and performance in patients with coronary artery disease (CAD).METHODS: This retrospective study consisted of 171 patients (258 lesions) implanted with Evermine 50 EES for managing CAD. We analyzed the major adverse cardiac events (MACE) incidence, defined as a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (ID-TLR) at 6-, 12-, and 24-month follow-up.RESULTS: A total of 171 patients were included with a mean age of 57.85 ± 10.05 years, of which, 139 (81.29%) were men, 69 (40.35%) were hypertensive, and 70 (40.94%) were diabetic. The incidence of MACE was 1 (0.58%), 3 (1.81%), and 4 (2.42%) at 6-, 12-, and 24-month follow-up, respectively. There were three cases (1.82%) of cardiac death and one case (0.61%) of ID-TLR up to 24 months. None of the patients was presented with definite or probable stent thrombosis (ST).CONCLUSION: This study demonstrated that implantation of ultrathin strut Evermine 50 EES resulted in a low rate of incidence of MACE, indicating a favourable clinical safety and performance profile of Evermine 50 EES in patients with CAD [Clinical Trials Registry-India (CTRI) Number: CTRI/2017/09/009939)].
https://arya.mui.ac.ir/article_10732_860fa63a6d001cef63daf081a3d0df98.pdf
2020-07-05
130
135
10.22122/arya.v16i3.1827
Coronary Artery Disease
Drug-Eluting Stent
Everolimus
Percutaneous Coronary Intervention
Suresh
Patted
patted@mailinator.com
1
Professor, Department of Cardiology, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India
AUTHOR
Ashok
Thakkar
ashok.thakkar@merillife.com
2
Head, Department of Clinical Research, Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India
LEAD_AUTHOR
von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): A three-arm, randomised, non-inferiority trial. Lancet 2016; 388(10060): 2607-17.
1
Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: Pthophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol 2012; 59(15): 1337-49.
2
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6(9): 914-22.
3
Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011; 58(18): 1844-54.
4
de Winter RJ, Katagiri Y, Asano T, Milewski KP, Lurz P, Buszman P, et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): A randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet 2018; 391(10119): 431-40.
5
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58(24): e44-122.
6
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2016; 68(10): 1082-115.
7
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115(17): 2344-51.
8
Lemos PA, Chandwani P, Saxena S, Ramachandran PK, Abhyankar A, Campos CM, et al. Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open 2016; 6(2): e010028.
9
Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 2016; 387(10013): 31-9.
10
Jimenez VA, Iniguez A, Baz JA, Valdes M, Ortiz A, Vuilliomenet A, et al. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy. Cardiovasc Revasc Med 2016; 17(6): 355-61.
11
Zhang H, Wang X, Deng W, Wang S, Ge J, Toft E. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes.
12
Medicine (Baltimore) 2016; 95(38): e4820.
13
Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation 2018; 138(20): 2216-26.
14
Milewski K, Gasior P, Samborski S, Buszman PP, Blachut A, Wojtaszczyk A, et al. Evaluation of safety and efficacy of NexGen - an ultrathin strut and hybrid cell design cobalt-chromium bare metal stent implanted in a real life patient population-the Polish NexGen Registry. Postepy Kardiol Interwencyjnej 2016; 12(3): 217-23.
15
Patted SV, Patted AS, Turiya PK, Thakkar AS. Clinical Outcomes of World's Thinnest (50 mumr) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients. Cardiol Res 2018; 9(6): 370-7.
16
Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial. Lancet 2014; 384(9960): 2111-22.
17
Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103(23): 2816-21.
18
Otikunta AN, Hosad UK, Reddy YVS, Eruvaram S, Srinivas R, Garg R, et al. Analysis of 12 months clinical outcomes associated with implantation of ultrathin (60 mum) bare metal stent in an
19
unselected real-world population with coronary artery disease. J Clin Diagn Res 2017; 11(5): OC12-OC16.
20
Wijns W, Suttorp MJ, Zagozdzon L, Morice MC, McClean D, Stella P, et al. Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: Two-year outcomes from the DESSOLVE I and II trials. EuroIntervention 2015; 11(5): 20150307-02.
21
Raber L, Kelbak H, Taniwaki M, Ostojic M, Heg D, Baumbach A, et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv 2014; 7(3): 355-64.
22
Natsuaki M, Kozuma K, Morimoto T, Shiomi H, Kimura T. Two-year outcome of a randomized trial comparing second-generation drug-eluting stents using biodegradable or durable polymer. JAMA 2014; 311(20): 2125-7.
23
Kok MM, Zocca P, Buiten RA, Danse PW, Schotborgh CE, Scholte M, et al. Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. EuroIntervention 2018; 14(8): 915-23.
24
Buiten RA, Ploumen EH, Zocca P, Doggen CJ, Jessurun GA, Schotborgh CE, et al. Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years. JACC Cardiovasc Interv 2020; 13(9): 1100-9.
25
ORIGINAL_ARTICLE
The effects of nanomicelle of curcumin on the matrix metalloproteinase (MMP-2, 9) activity and expression in patients with coronary artery disease (CAD): A randomized controlled clinical trial
BACKGROUND: Coronary artery disease (CAD) is the most common type of cardiovascular disease. Increasing the expression and activity of matrix metalloproteinases (MMPs) facilitates vascular remodeling and cardiovascular complications. Curcumin (the active ingredient of turmeric) is a potent natural anti-inflammatory agent, with cardiovascular protective effects. The present study was a clinical trial for investigating the effects of curcumin on activity and gene expression of MMP-2 and MMP-9 in patients with CAD.METHODS: In this study, 70 patients with CAD (with 40%-50% stenosis) were randomly divided into two groups of curcumin (80 mg nanomicelle per day) and placebo. The intervention lasted 3 months. The activity levels of MMP-2 and MMP-9 in serum samples of patients were measured using gelatin zymography assay before and after the intervention. MMP-2 and MMP-9 gene expression in peripheral blood mononuclear cells (PBMCs) was also analyzed using real-time polymerase chain reaction (PCR). Statistical significance was set at P < 0.0500.RESULTS: After 3 months of medication, the expression of MMP-9 produced by PBMCs significantly decreased in the curcumin group (0.811 ± 0.25) in comparison with the placebo group (2.23 ± 0.94) (P < 0.0001). Furthermore, the zymographic analysis showed that the administration of curcumin significantly inhibited the activity levels of MMP-2 (12469.7 ± 5308.64 pixels) and MMP-9 (14007.2 ± 5371.67 pixels) in comparison with that in patients receiving placebo (MMP-2: 17613.8 ± 5250.68 pixels; MMP-9: 20010.1 ± 3259.37 pixels) (P < 0.0500).CONCLUSION: Our results show that curcumin can significantly reduce the expression and activity of MMP-2 and MMP-9. Because of the anti-inflammatory effects of curcumin, this compound can be considered as a new strategy for the prevention of cardiovascular events.
https://arya.mui.ac.ir/article_10733_3e37e8f896544e6dbc38c99ee475e71a.pdf
2020-07-05
136
145
10.22122/arya.v16i3.1938
Curcumin
Matrix Metalloproteinases
Coronary Artery Disease
Marzieh
Mogharrabi
mogharrabi@mailinator.com
1
Associate Professor, Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hamid Reza
Rahimi
rahimi@mailinator.com
2
Assistant Professor, Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Shima
Hasanzadeh
hasanzadeh@mailinator.com
3
Associate Professor, Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mostafa
Dastani
dastani@mailinator.com
4
Associate Professor, Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Reza
Kazemi-Oskuee
kazemi-oskuee@mailinator.com
5
Associate Professor, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Saeed
Akhlaghi
akhlaghi@mailinator.com
6
Assistant Professor, Psychiatry and Behavioral Sciences Research Center AND Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohammad
Soukhtanloo
soukhtanloom@mums.ac.ir
7
Associate Professor, Pharmacological Research Center of Medicinal Plants AND Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Sanderson JE, Mayosi B, Yusuf S, Reddy S, Hu S, Chen Z, et al. Global burden of cardiovascular disease. Heart 2007; 93(10): 1175.
1
Haarala A. Inflammation and early atherosclerosis [Thesis]; Tampere, Finland: University of Tampere; 2012.
2
Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 2001; 40(9): 988-94.
3
Huang J. Role of matrix metalloproteinase-2 in therosclerosis and abdominal aortic aneurysms in apolipoprotein e deficient mice [Thesis]; Lexington, KY: University of Kentucky; 2005.
4
Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75(3): 539-45.
5
Momi S, Falcinelli E, Giannini S, Ruggeri L, Cecchetti L, Corazzi T, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med 2009; 206(11): 2365-79.
6
Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: Molecular aspects. Indian J Biochem Biophys 2012; 49(5):
7
Rahimi H, Jaafari M, Mohammadpour A, Abnous K, Ghayour Mobarhan M, Ramezanzadeh E, et al. Curcumin: Reintroduced Therapeutic Agent from Traditional Medicine for Alcoholic Liver Disease. Asia Pac J Med Toxicol 2015; 4(1): 25-30.
8
Rahimi HR, Nedaeinia R, Sepehri SA, Nikdoust S, Kazemi OR. Novel delivery system for natural products: Nano-curcumin formulations. Avicenna J Phytomed 2016; 6(4): 383-98.
9
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4(6):
10
Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci 2019; 22(3): 282-9.
11
Kosalova D, Bezakova L, Raekovac L, Mosovska S, Sturdik E. Therapeutic potential of curcumin in medicinal chemistry. Acta Chimica Slovaca 2013; 6(1): 89-99.
12
Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009; 133(2): 145-51.
13
Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270(42): 24995-5000.
14
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65(11): 1631-52.
15
Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J Nutr Biochem 2014; 25(2): 144-50.
16
Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab 2014; 12(4): e18081.
17
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9(2): 194-205.
18
Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial. Avicenna J Phytomed 2016; 6(5): 567-77.
19
Toth M, Fridman R. Assessment of Gelatinases (MMP-2 and MMP-9) by Gelatin Zymography. Methods Mol Med 2001; 57: 163-74.
20
Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91(4A): 4B-8B.
21
Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atheroscler Suppl 2001; 2(1): 9-14.
22
Simionescu M, Sima A. Morphology of atherosclerotic lesions. In: Wick G, Grundtman C, Editors. Inflammation and atherosclerosis. Berlin, Germany: Springer Science & Business Media; 2011. p. 19-37.
23
Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59(4): 812-23.
24
Shishodia S, Sethi G, Aggarwal BB. Curcumin: Getting back to the roots. Ann N Y Acad Sci 2005; 1056: 206-17.
25
Saja K, Babu MS, Karunagaran D, Sudhakaran PR. Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol 2007; 7(13): 1659-67.
26
Kohli S, Chhabra A, Jaiswal A, Rustagi Y, Sharma M, Rani V. Curcumin suppresses gelatinase B mediated norepinephrine induced stress in H9c2 cardiomyocytes. PLoS One 2013; 8(10): e76519.
27
Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, et al. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: Crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res 2002; 93(12): 1378-85.
28
Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011; 12(3): 332-47.
29
Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001; 50(3): 556-65.
30
Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 2006; 45(5): 320-32.
31
Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 2001; 151: 121-48.
32
Parodi FE, Mao D, Ennis TL, Pagano MB, Thompson RW. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann Vasc Surg 2006; 20(3): 360-8.
33
Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Tamaki M, et al. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation. Histochem Cell Biol 1998; 109(2): 97-102.
34
Newby AC, Zaltsman AB. Fibrous cap formation or destruction-the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999; 41(2): 345-60.
35
Zhong Y, Yu W, Feng J, Fan Z, Li J. Curcumin suppresses tumor necrosis factor-alpha-induced matrix metalloproteinase-2 expression and activity in rat vascular smooth muscle cells via the NF-kappaB pathway. Exp Ther Med 2014; 7(6): 1653-8.
36
Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, et al. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 2010; 49(9): 783-97.
37
Stoica G, Lungu G. Role of MMP2 in Brain Metastasis. In: Hayat MA, Editor. Tumors of the central nervous system, volume 13: Types of tumors, diagnosis, ultrasonography, surgery, brain metastasis, and general CNS diseases. Berlin, Germany: Springer Science & Business Media; 2014. p. 195-205.
38
Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol 2005; 288(3): C659-C668.
39
Qin L, Yang YB, Tuo QH, Zhu BY, Chen LX, Zhang L, et al. Effects and underlying mechanisms of curcumin on the proliferation of vascular smooth muscle cells induced by Chol: MbetaCD. Biochem Biophys Res Commun 2009; 379(2): 277-82.
40
Jana S, Paul S, Swarnakar S. Curcumin as anti-endometriotic agent: Implication of MMP-3 and intrinsic apoptotic pathway. Biochem Pharmacol 2012; 83(6): 797-804.
41
Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89(12): 1092-103.
42
Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000; 437(4): 396-405.
43
Nagashima H, Aoka Y, Sakomura Y, Uto K, Sakuta A, Aomi S, et al. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg 2004; 39(2): 447-53.
44
Li X, Lu Y, Sun Y, Zhang Q. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Int J Clin Exp Pathol 2015; 8(6): 7247-53.
45
ORIGINAL_ARTICLE
Recurrent cardiac and skin myxomas along with acromegaly: A case report of carney complex
BACKGROUND: Carney complex (CNC) is an uncommon multisystem endocrine disorder with significant variability of clinical manifestations including mucocutaneous areas (pigmented lesions, myxomas, blue nevi, etc.), endocrine tumors (adrenal, pituitary, thyroid glands, or testicles), and non-endocrine tumors [cardiac myxomas, psammomatous melanotic schwannomas (PMS), breast myxomas as well as ductal adenomas, and osteochondromyxomas]. To our knowledge, this is the second report of CNC in Iran, presenting with typical manifestations.Case Report: A 29-year-old man was referred to our clinic to evaluate the likelihood of CNC because of recurrent cardiac myxomas. He sometimes suffered from self-limited episodes of non-exertional palpitation, dyspnea, weakness, and pallor. He had some features of acromegaly (such as increase in acral size and frontal bossing). The laboratory tests revealed a high insulin-like growth factor 1 (IGF1) level, with no growth hormone (GH) suppression after oral glucose tolerance test (OGTT). Pituitary magnetic resonance imaging (MRI) showed a microadenoma (5.79 × 2.80 mm) of the pituitary gland; then, he was diagnosed with CNC, having the following major criteria: recurrent cardiac myxomas, skin myxomas, and acromegaly due to GH pituitary microadenoma, as well as minor criteria: multiple cafe´-au-lait (CAL) spots, several skin tags and moles, and thyroid nodules. In this patient, laboratory tests for Cushing’s syndrome were equivocal, whereas pheochromocytoma was proven biochemically but unexpectedly pathology did not confirm it. Rather, the pathology of the right adrenocortical specimen revealed nodular hyperplasia.CONCLUSION: For patients with recurrent cardiac myxoma, especially with skin myxoma, the diagnosis of CNC should be considered and the search for other associations should be done even in an asymptomatic patient.
https://arya.mui.ac.ir/article_10734_f684c8555da33e6a989ca17af1488feb.pdf
2020-07-05
146
150
10.22122/arya.v16i3.2080
Carney Complex
Acromegaly
Myxoma
Zivar
Shirinpour
shirinpour@mailinator.com
1
Assistant Professor, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Zahra
Farhangiyan
dr.farhangiyan.z@gmail.com
2
Assistant Professor, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
Nehzat
Akiash
akiash@mailinator.com
3
Assistant Professor, Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Homeira
Rashidi
rashidi@mailinator.com
4
Associate Professor, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64(4): 270-83.
1
Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86(9): 4041-6.
2
Correa R, Salpea P, Stratakis CA. Carney complex: An update. Eur J Endocrinol 2015; 173(4): M85-M97.
3
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase a type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26(1): 89-92.
4
Almeida MQ, Stratakis CA. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010; 24(6): 907-14.
5
Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing's syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(5): 1526-40.
6
Talaei A, Aminorroaya A, Taheri D, Mahdavi KN. Carney complex presenting with a unilateral adrenocortical nodule: A case report. J Med Case Rep 2014; 8: 38.
7
Chinchurreta-Capote A, Trueba A, Hernandez FJ, Pinas P, Lopez S, Tena ME, et al. Ocular findings in Carney complex. Arch Soc Esp Oftalmol 2006; 81(12): 709-11.
8
Obeid AI, Marvasti M, Parker F, Rosenberg J. Comparison of transthoracic and transesophageal echocardiography in diagnosis of left atrial myxoma. Am J Cardiol 1989; 63(13): 1006-8.
9
Edwards A, Bermudez C, Piwonka G, Berr ML, Zamorano J, Larrain E, et al. Carney's syndrome: complex myxomas. Report of four cases and review of the literature. Cardiovasc Surg 2002; 10(3): 264-75.
10
Courcoutsakis NA, Tatsi C, Patronas NJ, Lee CC, Prassopoulos PK, Stratakis CA. The complex of myxomas, spotty skin pigmentation and endocrine overactivity (Carney complex): imaging findings with clinical and pathological correlation. Insights Imaging 2013; 4(1): 119-33.
11
Iwata T, Tamanaha T, Koezuka R, Tochiya M, Makino H, Kishimoto I, et al. Germline deletion and a somatic mutation of the PRKAR1A gene in a Carney complex-related pituitary adenoma. Eur J Endocrinol 2015; 172(1): K5-10.
12
Birla S, Aggarwal S, Sharma A, Tandon N. Rare association of acromegaly with left atrial myxoma in Carney's complex due to novel PRKAR1A mutation. Endocrinol Diabetes Metab Case Rep 2014; 2014: 140023.
13
Hamza E, Hadjkacem F, Ghorbel D, Mnif F, Rekik N, Mnif M, et al. Cushing's syndrome revealing carney complex: A case report. Endocrinol Metab Int J 2017; 5(4): 275-9.
14
Holm M, Hoei-Hansen CE, Rajpert-De ME, Skakkebaek NE. Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle. J Urol 2003; 170(4 Pt 1): 1163-7.
15
Liu Q, Tong D, Liu G, Yi Y, Zhang D, Zhang J, et al. Carney complex with PRKAR1A gene mutation: A case report and literature review. Medicine (Baltimore) 2017; 96(50): e8999.
16
Tan IB, Ang KK, Ching BC, Mohan C, Toh CK, Tan MH. Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: A meta-analysis and systematic review. Cancer 2010; 116(19): 4520-32.
17
ORIGINAL_ARTICLE
Using technology and electronic devices to provide cardiac rehabilitation services
This article does not have an abstract
https://arya.mui.ac.ir/article_10735_dc7bc013389336ad7e8609fa8e55469b.pdf
2020-07-05
151
152
10.22122/arya.v16i3.2069
Mohammad
Rafati-Fard
rafati2821@gmail.com
1
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Tirimacco R, Tideman P. Alternative models of cardiac rehabilitation: A systematic review. Eur J Prev Cardiol 2015; 22(1): 35-74.
1
Latif S, Rana R, Qadir J, Ali A, Imran MA, Younis MS. mobile health in the developing world: Review of literature and lessons from a case study. IEEE Access 2017; 5: 11540-56.
2
Beatty AL, Fukuoka Y, Whooley MA. Using mobile technology for cardiac rehabilitation: A review and framework for development and evaluation. J Am Heart Assoc 2013; 2(6): e000568.
3
Xu L, Li F, Zhou C, Li J, Hong C, Tong Q. Theeffect of mobile applications for improving adherence in cardiac rehabilitation: A systematic review and meta-analysis. BMC Cardiovasc Disord 2019; 19(1): 166.
4
Sharma A, Harrington RA, McClellan MB, Turakhia MP, Eapen ZJ, Steinhubl S, et al. Using digital health technology to better generate evidence and deliver evidence-based care. J Am Coll Cardiol 2018; 71(23): 2680-90.
5
Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary prevention of cardiovascular disease: A systematic review. BMC Cardiovasc Disord 2018; 18(1): 25.
6
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue
https://arya.mui.ac.ir/article_10728_39ca8749a7e9edeb02eddf14e3f420f1.pdf
2020-05-01
10.22122/arya.v16i3.2349
Index
Journal
aryaeditor4@gmail.com
1
Arya
LEAD_AUTHOR